Cancer as an overhealing wound: An old hypothesis revisited

Nature Reviews Molecular Cell Biology

Volumn 9, Issue 8, 2008, Pages 628-638

  Schäfer, Matthias ^a   Werner, Sabine ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBROBLAST GROWTH FACTOR 2; HISTAMINE; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; STAT3 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN A;

ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; EPITHELIZATION; GENE FUNCTION; GRANULATION TISSUE; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE PERMEABILITY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; WOUND HEALING;

ANIMALS; CICATRIX; EPITHELIUM; EXTRACELLULAR MATRIX; FIBRIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; WOUND HEALING;

MUS;

EID: 47749139256     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm2455     Document Type: Review

References (108)

1. Reed, B. R. & Clark, R. A. Cutaneous tissue repair: practical implications of current knowledge. II. J. Am. Acad. Dermatol. 13, 919-941 (1985).
2. Virchow, R. Virchow, R. Aetiologie der neoplastischen Geschwulste/Pathogenie der neoplastischen Geschwulste. (Verlag von August Hirschwald, Berlin, Germany, 1863).
3. Dunham, L. J. Cancer in man at site of prior benign lesion of skin or mucous membrane: a review. Cancer Res. 32, 1359-1374 (1972).
4. Haddow, A. Molecular repair, wound healing, and carcinogenesis: tumor production a possible overhealing? Adv. Cancer Res. 16, 181-234 (1972).
5. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986). In this paper, H. Dvorak formulated his famous hypothesis that tumours are wounds that do not heal, and he describes the underlying cellular basis.
6. Dolberg, D. S., Hollingsworth, R., Hertle, M. & Bissell, M. J. Wounding and its role in RSV-mediated tumor formation. Science 230, 676-678 (1985). The first demonstration that tumours preferentially grow at sites of wounding in retrovirus-infected chickens.
7. Martins-Green, M., Boudreau, N. & Bissell, M. J. Inflammation is responsible for the development of wound-induced tumors in chickens infected with Rous sarcoma virus. Cancer Res. 54, 4334-4341 (1994).
8. Schuh, A. C., Keating, S. J., Monteclaro, F. S., Vogt, P. K. & Breitman, M. L. Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice. Nature 346, 756-760 (1990).
9. Drew, A. F., Liu, H., Davidson, J. M., Daugherty, C. C. & Degen, J. L. Wound-healing defects in mice lacking fibrinogen. Blood 97, 3691-3698 (2001).
10. Sakai, T. et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature Med. 7, 324-330 (2001).
11. Weller, K., Foitzik, K., Paus, R., Syska, W. & Maurer, M. Mast cells are required for normal healing of skin wounds in mice. FASEB J. 20, 2366-2368 (2006).
12. Leibovich, S. J. & Ross, R. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am. J. Pathol. 78, 71-100 (1975).
13. Martin, P. & Leibovich, S. J. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol. 15, 599-607 (2005). Summarizes the positive and negative effects of inflammation on the wound-repair process.
14. Eming, S. A., Krieg, T. & Davidson, J. M. Inflammation in wound repair: molecular and cellular mechanisms. J. Invest. Dermatol. 127, 514-525 (2007).
15. Martin, P. et al. Wound healing in the PU.1 null mouse - tissue repair is not dependent on inflammatory cells. Curr. Biol. 13, 1122-1128 (2003).
16. Dovi, J. V., He, L. K. & DiPietro, L. A. Accelerated wound closure in neutrophil-depleted mice. J. Leukoc. Biol. 73, 448-455 (2003).
17. Kumin, A. et al. Peroxiredoxin 6 is required for blood vessel integrity in wounded skin. J. Cell Biol. 179, 747-760 (2007).
18. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24-37 (2006).
19. Balkwill, F., Charles, K. A. & Mantovani, A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7, 211-217 (2005). References 18 and 19 summarize the current knowledge on the role of inflammation in cancer development and progression.
20. Allavena, P., Sica, A., Garlanda, C. & Mantovani, A. The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222, 155-161 (2008).
21. Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263-266 (2006). Summarizes the different functions of macrophages in cancer that are also relevant for the woundhealing process.
22. Eming, S. A. et al. Accelerated wound closure in mice deficient for interleukin-10. Am. J. Pathol. 170, 188-202 (2007).
23. Hussain, S. P., Hofseth, L. J. & Harris, C. C. Radical causes of cancer. Nature Rev. Cancer 3, 276-285 (2003).
24. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008).
25. + T cell tolerance in cancer. Nature Med. 13, 828-835 (2007).
26. Albini, A. & Sporn, M. B. The tumour microenvironment as a target for chemoprevention. Nature Rev. Cancer 7, 139-147 (2007).
27. Muller-Decker, K., Hirschner, W., Marks, F. & Furstenberger, G. The effects of cyclooxygenase isozyme inhibition on incisional wound healing in mouse skin. J. Invest. Dermatol. 119, 1189-1195 (2002).
28. Subbaramaiah, K. & Dannenberg, A. J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24, 96-102 (2003).
29. Braun, S. et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol. Cell. Biol. 22, 5492-5505 (2002).
30. Yu, X. & Kensler, T. Nrf2 as a target for cancer chemoprevention. Mutat. Res. 591, 93-102 (2005).
31. Martin, P. Wound healing - aiming for perfect skin regeneration. Science 276, 75-81 (1997).
32. Grose, R. et al. A crucial role of β 1 integrins for keratinocyte migration in vitro and during cutaneous wound repair. Development 129, 2303-2315 (2002).
33. White, D. E. et al. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159-170 (2004).
34. Romer, J. et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med. 2, 287-292 (1996).
35. Lund, L. R. et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 18, 4645-4656 (1999).
36. Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 161-174 (2002).
37. Florin, L., Maas-Szabowski, N., Werner, S., Szabowski, A. & Angel, P. Increased keratinocyte proliferation by JUN-dependent expression of PTN and SDF-1 in fibroblasts. J. Cell Sci. 118, 1981-1989 (2005).
38. Avniel, S. et al. Involvement of the CXCL12/CXCR4 pathway in the recovery of skin following burns. J. Invest. Dermatol. 126, 468-476 (2006).
39. Ceradini, D. J. et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nature Med. 10, 858-864 (2004).
40. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005). Describes the important role of carcinoma-associated fibroblasts for tumour growth and the underlying mechanisms of action.
41. Chmielowiec, J. et al. c-Met is essential for wound healing in the skin. J. Cell Biol. 177, 151-162 (2007).
42. Werner, S. & Grose, R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 83, 835-870 (2003).
43. Benvenuti, S. & Comoglio, P. M. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell Physiol. 213, 316-325 (2007).
44. Sibilia, M. et al. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75, 770-787 (2007).
45. Sano, S., Chan, K. S. & Digiovanni, J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J. Dermatol. Sci. 50, 1-14 (2008).
46. Amendt, C., Schirmacher, P., Weber, H. & Blessing, M. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17, 25-34 (1998).
47. Ashcroft, G. S. et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol. 1, 260-266 (1999).
48. Wakefield, L. M. & Roberts, A. B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12, 22-29 (2002).
49. Werner, S. et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 266, 819-822 (1994). The first study to use transgenic mice to study wound repair.
50. Grose, R. et al. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 26, 1268-1278 (2007).
51. Tse, J. C. & Kalluri, R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell Biochem. 101, 816-829 (2007).
52. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
53. Janda, E. et al. Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell Biol. 156, 299-314 (2002).
54. Radisky, D. C. et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123-127 (2005).
55. Ting, S. B. et al. A homolog of Drosophila grainy head is essential for epidermal integrity in mice. Science 308, 411-413 (2005).
56. Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
57. Tepper, O. M. et al. Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells. Blood 105, 1068-1077 (2005).
58. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971). In this paper, J. Folkman formulates the important hypothesis that angiogenesis is a prerequisite for tumour growth.
59. Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T. & Alitalo, K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156, 1499-1504 (2000).
60. Saharinen, P., Tammela, T., Karkkainen, M. J. & Alitalo, K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25, 387-395 (2004).
61. Liersch, R. & Detmar, M. Lymphangiogenesis in development and disease. J. Thromb. Haemost. 98, 304-310 (2007).
62. Ferrara, N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10-14 (2002).
63. Rossiter, H. et al. Loss of vascular endothelial growth factor A activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res. 64, 3508-3516 (2004).
64. Hong, Y. K. et al. VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the α1β1 and α2β1 integrins. FASEB J. 18, 1111-1113 (2004).
65. Larcher, F., Murillas, R., Bolontrade, M., Conti, C. J. & Jorcano, J. L. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17, 303-311 (1998).
66. Hirakawa, S. et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201, 1089-1099 (2005).
67. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575-583 (2001).
68. Cianfarani, F. et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am. J. Pathol. 169, 1167-1182 (2006).
69. Marcellini, M. et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am. J. Pathol. 169, 643-654 (2006).
70. Saaristo, A. et al. Vascular endothelial growth factor-C accelerates diabetic wound healing. Am. J. Pathol. 169, 1080-1087 (2006).
71. Hirakawa, S. et al. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109, 1010-1017 (2007).
72. Streit, M. et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J. 19, 3272-3282 (2000).
73. Streit, M. et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am. J. Pathol. 155, 441-452 (1999).
74. Luster, A. D., Cardiff, R. D., MacLean, J. A., Crowe, K. & Granstein, R. D. Delayed wound healing and disorganized neovascularization in transgenic mice expressing the IP-10 chemokine. Proc. Assoc. Am. Physicians 110, 183-196 (1998).
75. Arenberg, D. A. et al. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184, 981-992 (1996).
76. O'Reilly, M. S. et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285 (1997).
77. Bloch, W. et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 14, 2373-2376 (2000).
78. Lange-Asschenfeldt, B. et al. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J. Invest. Dermatol. 117, 1036-1041 (2001).
79. Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788-1795 (2007).
80. Opalenik, S. R. & Davidson, J. M. Fibroblast differentiation of bone marrow-derived cells during wound repair. FASEB J. 19, 1561-1563 (2005).
81. Werner, S. & Smola, H. Paracrine regulation of keratinocyte proliferation and differentiation. Trends Cell Biol. 11, 143-146 (2001).
82. Radisky, D. C., Kenny, P. A. & Bissell, M. J. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J. Cell Biochem. 101, 830-839 (2007).
83. Gaggioli, C. et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nature Cell Biol. 9, 1392-1400 (2007).
84. Direkze, N. C. et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 64, 8492-8495 (2004).
85. Iyer, V. R. et al. The transcriptional program in the response of human fibroblasts to serum. Science 283, 83-87 (1999).
86. Cooper, L., Johnson, C., Burslem, F. & Martin, P. Wound healing and inflammation genes revealed by array analysis of 'macrophageless' PU.1 null mice. Genome Biol. 6, R5 (2005).
87. Li, W. et al. Extracellular heat shock protein-90α: linking hypoxia to skin cell motility and wound healing. EMBO J. 26, 1221-1233 (2007).
88. Eustace, B. K. et al. Functional proteomic screens reveal an essential extracellular role for hsp90 α in cancer cell invasiveness. Nature Cell Biol. 6, 507-514 (2004).
89. Ostman, A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev. 15, 275-286 (2004).
90. Gao, Z. et al. Deletion of the PDGFR-β gene affects key fibroblast functions important for wound healing. J. Biol. Chem. 280, 9375-9389 (2005).
91. Pietras, K. et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. Clin. Cancer Res. 9, 3779-3787 (2003).
92. Rajkumar, V. S. et al. Platelet-derived growth factor-β receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am. J. Pathol. 169, 2254-2265 (2006).
93. Distler, J. H. et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 56, 311-322 (2007).
94. Steed, D. L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast. Reconstr Surg. 117, S143-S149 (2006).
95. Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Rev. Mol. Cell Biol. 3, 349-363 (2002).
96. Shah, M., Foreman, D. M. & Ferguson, M. W. Neutralisation of TGF-β 1 and TGF-β 2 or exogenous addition of TGF-β 3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108, 985-1002 (1995).
97. Cheon, S. S. et al. β-catenin regulates wound size and mediates the effect of TGF-β in cutaneous healing. FASEB J. 20, 692-701 (2006).
98. Cheon, S. S. et al. β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc. Natl Acad. Sci. USA 99, 6973-6978 (2002).
99. Alman, B. A., Li, C., Pajerski, M. E., Diaz-Cano, S. & Wolfe, H. J. Increased β-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am. J. Pathol. 151, 329-334 (1997).
100. Bhowmick, N. A. et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303, 848-851 (2004).
101. Stover, D. G., Bierie, B. & Moses, H. L. A delicate balance: TGF-β and the tumor microenvironment. J. Cell Biochem. 101, 851-861 (2007).
102. Mori, R., Shaw, T. J. & Martin, P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J. Exp. Med. 205, 43-51 (2008).
103. El-Tanani, M. K. et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 17, 463-474 (2006).
104. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
105. Chang, H. Y. et al. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2, E7 (2004). Reports on the parallels in the gene-expression pattern between malignant tumours and serum-treated fibroblasts.
106. Riss, J. et al. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res. 66, 7216-7224 (2006).
107. Pedersen, T. X. et al. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. Oncogene 22, 3964-3976 (2003).
108. Thorey, I. S. et al. Transgenic mice reveal novel activities of growth hormone in wound repair, angiogenesis, and myofibroblast differentiation. J. Biol. Chem. 279, 26674-26684 (2004).